Patents by Inventor Cen Xu

Cen Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210095016
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
    Type: Application
    Filed: September 24, 2020
    Publication date: April 1, 2021
    Applicant: AMGEN INC.
    Inventors: Agnes E. HAMBURGER, Cen XU, Hong SUN, Yuan D. SHIH, Dohan WEERARATNE
  • Patent number: 10934362
    Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: March 2, 2021
    Assignee: AMGEN INC.
    Inventors: Gunasekaran Kannan, Ling Liu, Edward J. Belouski, Cen Xu
  • Publication number: 20210047422
    Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
    Type: Application
    Filed: August 27, 2020
    Publication date: February 18, 2021
    Applicant: AMGEN INC.
    Inventors: Gunasekaran KANNAN, Ling LIU, Edward J. BELOUSKI, Cen XU
  • Publication number: 20210017261
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: July 1, 2020
    Publication date: January 21, 2021
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Patent number: 10822408
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 3, 2020
    Assignee: AMGEN INC.
    Inventors: Agnes E. Hamburger, Cen Xu, Hong Sun, Yuan D. Shih, Dohan Weeraratne
  • Patent number: 10793631
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: October 6, 2020
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Patent number: 10738110
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 11, 2020
    Assignee: AMGEN INC.
    Inventors: Neeraj Jagdish Agrawal, Kevin Graham, Agnes Eva Hamburger, Christopher Mohr, Derek E. Piper, Kenneth William Walker, Zhulun Wang, Cen Xu
  • Publication number: 20200172614
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Application
    Filed: September 16, 2019
    Publication date: June 4, 2020
    Applicant: AMGEN INC.
    Inventors: Cen XU, Agnes Eva HAMBURGER
  • Patent number: 10472417
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: November 12, 2019
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Publication number: 20190218279
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Patent number: 10294298
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 21, 2019
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Publication number: 20180362645
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Application
    Filed: June 25, 2018
    Publication date: December 20, 2018
    Applicant: AMGEN INC.
    Inventors: Cen XU, Agnes Eva HAMBURGER
  • Publication number: 20180362643
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
    Type: Application
    Filed: December 15, 2016
    Publication date: December 20, 2018
    Applicant: AMGEN INC.
    Inventors: Agnes E. HAMBURGER, Cen XU, Hong SUN, Yuan D. SHIH, Dohan WEERARATNE
  • Patent number: 10053507
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 21, 2018
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Publication number: 20180142029
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: November 28, 2017
    Publication date: May 24, 2018
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • Publication number: 20180094055
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Application
    Filed: October 18, 2017
    Publication date: April 5, 2018
    Applicant: AMGEN INC.
    Inventors: Cen XU, Agnes Eva HAMBURGER
  • Patent number: 9862771
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 9, 2018
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Patent number: D883248
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: May 5, 2020
    Assignee: YEALINK (XIAMEN) NETWORK TECHNOLOGY CO., LTD.
    Inventors: Jian Cheng Zhang, Wei Cen Xu, Chun Sheng Su, Jing Feng Su, Lian Chang Zhang, Ji Wei Zhou
  • Patent number: D885360
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 26, 2020
    Assignee: YEALINK (XIAMEN) NETWORK TECHNOLOGY CO., LTD.
    Inventors: Jian Cheng Zhang, Wei Cen Xu, Chun Sheng Su, Jing Feng Su, Lian Chang Zhang, Ji Wei Zhou
  • Patent number: D886075
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: June 2, 2020
    Assignee: YEALINK (XIAMEN) NETWORK TECHNOLOGY CO., LTD.
    Inventors: Jian Cheng Zhang, Wei Cen Xu, Chun Sheng Su, Jing Feng Su, Lian Chang Zhang, Ji Wei Zhou